Please try another search
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Name | Age | Since | Title |
---|---|---|---|
Joshua A. Kazam | 44 | 2017 | Co-Founder & Director |
Arie S. Belldegrun | 72 | 2017 | Co-Founder & Executive Chairman |
David D. Chang | 61 | 2018 | Co-Founder, President, CEO & Director |
John A. DeYoung | 58 | 2018 | Independent Director |
Matthew Porteus | 56 | - | Member of Scientific Advisory Board |
Antonius N.M. Schumacher | - | - | Chairman of Scientific Advisory Board |
Donald B. Kohn | - | - | Member of Scientific Advisory Board |
Malcolm K. Brenner | 69 | 2019 | Member of Scientific Advisory Board |
Todd B. Sisitsky | 51 | 2018 | Independent Director |
Franz Bernhard Humer | 76 | 2018 | Independent Director |
David Bonderman | 80 | 2018 | Lead Independent Director |
Deborah M. Messemer | 64 | 2018 | Independent Director |
Stephen J. Forman | 73 | 2019 | Member of Scientific Advisory Board |
Stephan A. Grupp | - | 2020 | Member of Scientific Advisory Board |
Jae Park | - | 2021 | Member of Scientific Advisory Board |
Thomas F. Gajewski | - | 2020 | Member of Scientific Advisory Board |
Stephen L. Mayo | 61 | 2022 | Independent Director |
Vicki L. Sato | 74 | 2021 | Independent Director |
Elizabeth A. Barrett | 61 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review